Xenon Pharmaceuticals Announces Board and Officer Changes
Ticker: XENE · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1582313
| Field | Detail |
|---|---|
| Company | Xenon Pharmaceuticals Inc. (XENE) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $540,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, management-change
TL;DR
Xenon Pharma reshuffled its board and execs as of Oct 15, 2025.
AI Summary
Xenon Pharmaceuticals Inc. announced on October 15, 2025, changes in its board and officer composition. The filing details the departure of certain directors and officers, the election of new directors, and updates to compensatory arrangements for its key executives. Specific names of departing and newly elected individuals are not provided in this excerpt, but the changes are effective as of October 15, 2025.
Why It Matters
Changes in a company's leadership and board composition can signal shifts in strategic direction or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing reports routine corporate governance changes and does not indicate significant financial or operational risks.
Key Players & Entities
- Xenon Pharmaceuticals Inc. (company) — Registrant
- October 15, 2025 (date) — Date of earliest event reported
- October 16, 2025 (date) — Date of report
FAQ
What specific roles have been affected by the changes at Xenon Pharmaceuticals Inc.?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers'.
When were these changes effective?
The earliest event reported is dated October 15, 2025, and the date of the report is October 16, 2025.
Is this a routine filing for Xenon Pharmaceuticals Inc.?
Yes, the filing is a Form 8-K, which is a Current Report filed to announce major corporate events that shareholders should know about.
What is the principal executive office address for Xenon Pharmaceuticals Inc.?
The address is 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8.
What is Xenon Pharmaceuticals Inc.'s telephone number?
The company's telephone number is (604) 484-3300.
Filing Stats: 1,498 words · 6 min read · ~5 pages · Grade level 11.1 · Accepted 2025-10-16 17:16:25
Key Financial Figures
- $540,000 — Mr. Kelly's annual base salary will be $540,000, and he will be eligible for an annual
Filing Documents
- xene-20251015.htm (8-K) — 63KB
- xene-ex10_1.htm (EX-10.1) — 202KB
- xene-ex99_1.htm (EX-99.1) — 20KB
- img2657600_0.jpg (GRAPHIC) — 235KB
- img2657600_1.jpg (GRAPHIC) — 235KB
- img2657600_2.jpg (GRAPHIC) — 235KB
- img189401473_0.jpg (GRAPHIC) — 20KB
- 0001193125-25-241546.txt ( ) — 1368KB
- xene-20251015.xsd (EX-101.SCH) — 30KB
- xene-20251015_htm.xml (XML) — 5KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 16, 2025, Xenon Pharmaceuticals Inc. (the "Company") announced that Thomas (Tucker) Kelly has been appointed to serve as the Company's Chief Financial Officer, effective October 15, 2025. In connection with his appointment, Mr. Kelly will serve as the Company's principal financial officer and principal accounting officer. Mr. Kelly, age 54, previously served as Executive Vice President, Chief Financial Officer and Treasurer of Deciphera Pharmaceuticals, Inc. from January 2019 until its acquisition by Ono Pharmaceutical Co., Ltd. in June 2024, and as Deciphera's Chief Financial Officer and Treasurer since February 2015. Before joining Deciphera, Mr. Kelly served as Chief Financial Officer of various public and private life sciences companies including AdvanDx, Inc., deCODE genetics, Inc., and Critical Therapeutics, Inc. Prior to these roles, Mr. Kelly was a life sciences investment banker at Robertson Stephens and Canaccord Adams, and earlier in his career was an attorney in the corporate and securities group of Foley Hoag LLP. Mr. Kelly earned a J.D. with honors from the University of Chicago Law School and a B.S. in Foreign Service, cum laude, from the Georgetown University School of Foreign Service. There are no arrangements or understandings between Mr. Kelly and any other person pursuant to which he was appointed as Chief Financial Officer. There are no family relationships between Mr. Kelly and any director or officer of the Company, nor does Mr. Kelly have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. In connection with his appointment as Chief Financial Officer, Mr. Kelly and the Company entered into a letter agreement that sets forth the terms and conditions of his employment (the "Employment Agreement"
01
Item 8.01 Other Events. On October 16, 2025, the Company issued a press release announcing the matters described above, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Employment Agreement, dated October 4, 2025, by and between the Company and Thomas Kelly. 99.1 Press Release issued by Xenon Pharmaceuticals Inc. dated October 16, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENON PHARMACEUTICALS INC. Date: October 16, 2025 By: /s/ Ian Mortimer Ian Mortimer President and Chief Executive Officer